Search

Velpatasvir

In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Velpatasvir as first line therapy … Both Canadian and American guidelines list Epclusa as a first line recommendation for all genotypes of HCV [L852, A19626].

Gadopiclenol

However, studies revealed that NSF was associated with linear GBCAs, not macrocyclic GBCAs, such as gadopiclenol. … It is indicated for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system and the body.

Influenza A virus A/Michigan/45/2015 X-275 (H1N1) hemagglutinin antigen (formaldehyde inactivated)

Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

Cerulenin

It is also shown to inhibit feeding and induce dramatic weight loss in mice. It is found naturally in the Cephalosporium caerulensfungus. … In fatty acid synthesis, reported to bind in equimolar ratio to b-keto-acyl-ACP synthase. In sterol synthesis, inhibits HMG-CoA synthetase activity.

Almonertinib

[A231859] On March 19, 2020, almonertinib was approved in China for the treatment of EGFR T790M+ non-small cell lung cancer.[A231864] Almonertinib was also approved by the EMA on February 20, 2026. … Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations.

Adenine

A purine base and a fundamental unit of adenine nucleotides.

Brexucabtagene autoleucel

These therapies differ in manufacturing methodology, viral vector, chimeric antigen choice, and the internal co-stimulatory domains of the chimeric antigen. … A216163, L15148] However, the preparation of brexucabtagene autoleucel, previously referred to as KTE-X19, uses a method of T cell enrichment that decreases the prevalence of CD19-expressing tumour cells in

Luteinizing hormone

Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)

Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

Influenza B virus B/Maryland/15/2016 BX-69A antigen (formaldehyde inactivated)

Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.